Proteome-wide and network pharmacology integration identifies sunitinib as a potential therapeutic for type 2 diabetes targets.

ABSTRACT:

Background

The proteome is vital for discovering therapeutic targets. We conducted a proteome-wide Mendelian randomization (MR) analysis to identify potential Type 2 Diabetes (T2D) biomarkers and therapeutic targets.

Methods

Data from deCODE Genetics (4907 proteins in 35,559 individuals) and the FinnGen study (65,085 T2D cases, 335,112 controls) were analyzed using inverse-variance weighted MR. Robustness was ensured through reverse MR and external cohort validation. Bayesian weighted MR further corroborated results. Additional analyses included protein-protein interaction (PPI) networks, pathway enrichment, druggability evaluation, and single-cell expression analysis.

Results

Proteome-wide MR analysis identified 233 proteins associated with T2D risk. After adjusting

SUBMITTER: Kong Y 

PROVIDER: S-EPMC12553910 | biostudies-literature | 2025

REPOSITORIES: biostudies-literature